Cost-effectiveness of alternative blood-screening strategies for West Nile virus in the United States

PLoS Medicine

Volumn 3, Issue 2, 2006, Pages 0211-0221

  Korves, Caroline T ^a,b   Goldie, Sue J ^c   Murray, Megan B ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c HARVARD CENTER FOR RISK ANALYSIS   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD EXAMINATION; BLOOD TRANSFUSION; COMPUTER ASSISTED DIAGNOSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; ENDEMIC DISEASE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE DEFICIENCY; INFECTION RATE; LIFE EXPECTANCY; MATHEMATICAL MODEL; NONHUMAN; NUCLEIC ACID TEST; QUESTIONNAIRE; RECIPIENT; SCREENING TEST; SEASONAL VARIATION; UNITED STATES; VIRUS DETECTION; VIRUS INFECTION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS; BLOOD; DISEASE TRANSMISSION; ECONOMICS; EVALUATION; IMMUNOCOMPROMISED PATIENT; MASS SCREENING; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; SEASON; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; WEST NILE FEVER;

BLOOD DONORS; BLOOD TRANSFUSION; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOCOMPROMISED HOST; MASS SCREENING; MODELS, ECONOMETRIC; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SEASONS; SENSITIVITY AND SPECIFICITY; UNITED STATES; WEST NILE FEVER;

EID: 33644845856     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030021     Document Type: Article

References (36)

1. Nash D, Mostashari F, Fine A, Miller J, O'Leary D, et al. (2001) The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 344: 1807-1814.
2. Huhn GD, Sejvar JJ, Montgomery SP, Dworkin MS (2003) West Nile virus in the United States: An update on an emerging infectious disease. Am Fam Physician 68: 653-660.
3. Centers for Disease Control and Prevention (2004) Update: West Nile virus screening of blood donations and transfusion-associated transmission - United States, 2003. MMWR Morb Mortal Wkly Rep 53: 281-284.
4. Bren L (2003) West Nile virus: Reducing the risk. FDA Consum 37: 20-27.
5. Busch MP, Dodd RY (2000) NAT and blood safety: What is the paradigm? Transfusion 40: 1157-1160.
6. Roback JD (2002) CMV and blood transfusions. Rev Med Virol 12: 211-219.
7. Sachs JD (2001) Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization. 213 p. Available: http://www.un.org/esa/ coordination/ecosoc/docs/RT.K.MacroeconomicsHealth.pdf. Accessed 27 December 2005.
8. Gold ML, Siegel JE, Russel LB, Weinstein MC (1996) Cost-effectiveness in health and medicine: The Report of the Panel on Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. 425 p.
9. Vamvakas EC, Taswell HF (1994) Long-term survival after blood transfusion. Transfusion 34: 471-477.
10. Biggerstaff BJ, Petersen LR (2002) Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City. Transfusion 42: 1019-1026.
11. Biggerstaff BJ, Petersen LR (2003) Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion 43: 1007-1017.
12. Mostashari F, Bunning ML, Kitsutani PT, Singer DA, Nash D, et al. (2001) Epidemic West Nile encephalitis, New York, 1999: Results of a household-based seroepidemiological survey. Lancet 358: 261-264.
13. Southam CM, Moore AE (1954) Induced virus infections in man by the Egypt isolates of West Nile virus. Am J Trop Med Hyg 3: 19-50.
14. Vamvakas EC, Goldstein R (2002) Four-year survival of transfusion recipients identified by hepatitis C lookback. Transfusion 42: 691-697.
15. Jeha LE, Sila CA, Lederman RJ, Prayson RA, Isada CM, et al. (2003) West Nile virus infection: A new acute paralytic illness. Neurology 61: 55-59.
16. Weiss D, Carr D, Kellachan J, Tan C, Phillips M, et al. (2001) Clinical findings of West Nile virus infection in hospitalized patients, New York and New Jersey, 2000. Emerg Infect Dis 7: 654-658.
17. Sejvar JJ, Haddad MB, Tierney BC, Campbell GL, Marfin AA, et al. (2003) Neurologic manifestations and outcome of West Nile virus infection. JAMA 290: 511-515.
18. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, et al. (2003) Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 349: 1236-1245.
19. Pepperell C, Rau N, Krajden S, Kern R, Humar A, et al. (2003) West Nile virus infection in 2002: Morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ 168: 1399-1405.
20. Klee AL, Maidin B, Edwin B, Poshni I, Mostashari F, et al. (2004) Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis 10: 1405-1411.
21. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, et al. (2004) Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 86: 28-40.
22. Ratterree MS, Gutierrez RA, Travassos da Rosa AP, Dille BJ, Beasley DW, et al. (2004) Experimental infection of rhesus macaques with West Nile virus: Level and duration of viremia and kinetics of the antibody response after infection. J Infect Dis 189: 669-676.
23. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, et al. (1993) The Beaver Dam Health Outcomes Study: Initial catalog of health-state quality factors. Med Decis Making 13: 89-102.
24. Institute of Medicine (2001) Vaccines for 21st Century: A tool for setting priorities. Washington (DC): National Academies Press. 460 p.
25. Livartowski A, Boucher J, Detournay B, Reinert P (1996) Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France. Vaccine 14: 495-500.
26. Shehata N, Kohli M, Detsky A (2004) The cost-effectiveness of screening blood donors for malaria by PCR. Transfusion 44: 217-228.
27. Villari P, Spielman A, Komar N, McDowell M, Timperi RJ (1995) The economic burden imposed by a residual case of eastern encephalitis. Am J Trop Med Hyg 52: 8-13.
28. Utz JT, Apperson CS, MacCormack JN, Salyers M, Dietz EJ, et al. (2003) Economic and social impacts of La Crosse encephalitis in western North Carolina. Am J Trop Med Hyg 69: 509-518.
29. AuBuchon JP, Birkmeyer JD, Busch MP (1997) Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion 37: 45-51.
30. Busch MP, Dodd RY, Lackritz EM, AuBuchon JP, Birkmeyer JD, et al. (1997) Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group. Transfusion 37: 1003-1011.
31. Jackson BR, Busch MP, Stramer SL, AuBuchon JP (2003) The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43: 721-729.
32. AuBuchon JP, Birkmeyer JD, Busch MP (1997) Safety of the blood supply in the United States: Opportunities and controversies. Ann Intern Med 127: 904-909.
33. Kilpatrick AM, Kramer LD, Campbell SR, Alleyne EO, Dobson AP, et al. (2005) West Nile virus risk assessment and the bridge vector paradigm. Emerg Infect Dis 11: 425-429.
34. Custer B, Tomasulo PA, Murphy EL, Caglioti S, Harpool D, et al. (2004) Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: Analysis of 2003 data to inform 2004 decision making. Transfusion 44: 1547-1554.
35. Goldblum N, Jasinska-Klingberg W, Klingberg MA, Marberg K, Sterk VV (1956) The natural history of West Nile Fever. I. Clinical observations during an epidemic in Israel. Am J Hyg 64: 259-269.
36. Hannoun C, Corniou B, Causse G, Panthier R (1967) Development of serum antibodies in 4 cases of West Nile virus infection. Ann Inst Pasteur (Paris) 113: 29-36.